McDermott Will & Schulte has advised Science Corp. on its negotiations with the University Hospital Schleswig-Holstein in Lübeck (UKSH) on the first commercial use of PRIMA, a retinal implant for the treatment of patients with geographic atrophy (GA) resulting from age-related macular degeneration (AMD), the firm announced on 19 October 2026.
According to the firm, PRIMA received CE certification from DEKRA under the EU Medical Device Regulation in July 2026, allowing it to be placed on the market in 30 European countries. PRIMA is the first and so far only CE-certified treatment for the restoration of form vision (reading letters, numbers and words).
Chambers and Co. since 2004.
Science Corp. develops medical devices and research hardware at various stages of the approval process. The company is headquartered in Alameda, California, and has further offices in Research Triangle Park, North Carolina, and in Paris, France.
The McDermott Will & Schulte team advising Science Corp. comprised Jana Grieb and Monika Richter (both Health & Life Sciences, Frankfurt), Marcus Fischer (counsel, tax, Frankfurt), Claus Färber (counsel, data protection, Munich) and Philip Uecker (associate, IP, Düsseldorf).
For detailed information, as well as the picture copyright, please see the law firm’s original article here: https://www.mcdermottlaw.com/de/news/mcdermott-beraet-science-corp-bei-verhandlungen-mit-universitaetsklinikum-luebeck-ueber-das-weltweit-erste-prima-implantat/
